The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.

The European Commission granted an approval under exceptional circumstances to InflaRx’s immunosuppressant. The European ...

Meridian Medical Technologies has won a new contract worth up to $129m from the US for the supply of its DuoDote nerve agent ...

Lyndra Therapeutics and Thermo Fisher Scientific have entered a strategic partnership for Lyndra's long-acting oral therapies ...

Santhera Pharmaceuticals has started launch preparations for its DMD drug Agamree (vamorolone) in the UK, after a ...

Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and ...

Eli Lilly has received approval from the US FDA for Omvoh to treat moderately to severely active Crohn's disease in the adult ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

Treating the growing problem of childhood obesity calls for exploring new approaches and treatments through well-designed ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.

At the JP Morgan Healthcare Conference 2025, Charles River CEO blamed low client spending, loss of a contract and other reasons for lower 2025 projections.

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.